Bristol Myers Squibb (BMY) has been the subject of various news related to its stock movements, earnings forecasts, and product developments. Despite market gains, the company's stock has shown fluctuation, with instances of both rise and fall. Employee initiatives to raise funds for cancer research reflect a strong company culture. The third-quarter earnings of the company are predicted to be strong. The company successfully overcome a $6.4 billion lawsuit related to a delayed cancer drug. BMY's recent advancements include FDA approvals of Breyanzi, a new CAR T Cell Therapy for specific lymphomas and a new type of schizophrenia drug. Despite forecasts of declining earnings, there is a bullish case presented for BMY on the back of strategic acquisitions, revenue increase, and high institutional ownership. Lastly, BMY is reported to have made cost cuts while posting a quarterly loss, alongside the reports of its Q2 2024 earnings.
Bristol-Myers Squibb BMY News Analytics from Thu, 14 Mar 2024 07:00:00 GMT to Sat, 26 Oct 2024 07:42:27 GMT -
Rating 3
- Innovation 6
- Information 7
- Rumor -5